Published in Haemophilia on September 01, 2004
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost (2012) 1.35
Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J (2009) 1.05
Animal models of hemophilia. Prog Mol Biol Transl Sci (2012) 1.04
A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood (2009) 0.97
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia (2012) 0.94
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost (2010) 0.92
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics (2009) 0.86
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood (2015) 0.84
Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag (2007) 0.83
Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics (2014) 0.83
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood (2016) 0.81
Allometry of factor VIII and informed scaling of next-generation therapeutic proteins. J Pharm Sci (2013) 0.78
A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach. Thromb Res (2012) 0.78
Inhibitors in previously treated patients: a review of the literature. Haemophilia (2010) 0.76
Key issues in inhibitor management in patients with haemophilia. Blood Transfus (2013) 0.76
Pediatric Dosing and Body Size in Biotherapeutics. Pharmaceutics (2010) 0.75
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A. J Blood Med (2016) 0.75
Patient and parent preferences for characteristics of prophylactic treatment in hemophilia. Patient Prefer Adherence (2015) 0.75
Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. J Blood Med (2016) 0.75
Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate(®)) in hemophilia A. J Blood Med (2016) 0.75
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med (1998) 4.39
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood (1998) 3.24
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med (1992) 3.21
NDR1, a pathogen-induced component required for Arabidopsis disease resistance. Science (1997) 3.16
Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J Cell Biol (1994) 2.95
Primary structural: analysis of the transplantation antigens of the murine H-2 major histocompatibility complex. Annu Rev Biochem (1981) 2.93
Error in blood-pressure measurement due to incorrect cuff size in obese patients. Lancet (1982) 2.56
Membrane targeting of the small GTPase Rab9 is accompanied by nucleotide exchange. Nature (1994) 2.50
Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia (2000) 2.48
Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth (2012) 2.30
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost (2004) 2.20
Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost (1998) 2.20
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol (1999) 2.14
The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia (2004) 1.92
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol (2006) 1.90
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost (2007) 1.72
Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol (2000) 1.70
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med (1992) 1.57
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia (2007) 1.54
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. J Intern Med (2001) 1.54
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53
Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol (1987) 1.53
Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia (2011) 1.47
A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia (2005) 1.46
Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med (1997) 1.44
[Control of oral anticoagulant therapy. The Quick method is one step back]. Lakartidningen (1993) 1.40
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood (1996) 1.39
Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol (2000) 1.38
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood (1997) 1.34
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Rab-GDI presents functional Rab9 to the intracellular transport machinery and contributes selectivity to Rab9 membrane recruitment. J Biol Chem (1994) 1.33
An intragenic deletion of the factor IX gene in a family with hemophilia B. J Clin Invest (1985) 1.32
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet (2001) 1.32
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol (1999) 1.32
Localization of the papain cleavage site of H-2 glycoproteins. Proc Natl Acad Sci U S A (1976) 1.28
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia (2002) 1.27
The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. J Clin Invest (1991) 1.26
The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia (2004) 1.26
Plasminogen deficiency. Haemophilia (2008) 1.22
Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol (1998) 1.22
Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol (1997) 1.19
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 1.18
Maternal serum alpha-fetoprotein screening for the detection of neural tube defects. West J Med (1983) 1.18
Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion (2001) 1.18
Chemical basis of the electrophoretic variation observed at the alcohol dehydrogenase locus of Drosophila melanogaster. Biochimie (1979) 1.17
Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. Blood (1999) 1.14
Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia (2004) 1.14
Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol (2006) 1.14
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia (2002) 1.14
Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia (1999) 1.14
Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost (2001) 1.12
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost (2008) 1.11
Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus. BMJ (1988) 1.11
Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med (1988) 1.11
A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia (2004) 1.10
The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia (2004) 1.10
Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood (1998) 1.09
Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood (1997) 1.08
Pathology of the liver in leukaemia and lymphoma. A study of 110 autopsies. Histopathology (1995) 1.08
The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia (2001) 1.08
Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia (2011) 1.07
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost (2009) 1.07
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost (2005) 1.06
Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost (2013) 1.05
Chemistry and synthetic development of misoprostol. Dig Dis Sci (1985) 1.05
Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence of the amino-terminal one hundred and seventy-three residues of the H-2Kb glycoprotein. Biochemistry (1980) 1.05
SC-29333: a potent inhibitor of canin gastric secretion. Am J Dig Dis (1976) 1.04
The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol (2000) 1.04
A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost (1997) 1.04
Further structural analysis of the murine H-2Kb glycoprotein using radiochemical methodology. Mol Immunol (1979) 1.03
Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia (2006) 1.03
The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth (2010) 1.02
EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res (2011) 1.02
Plasminogen activator inhibitor type 1 deficiency. Haemophilia (2008) 1.02
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol (1998) 1.02
Erythropoietin response to critical illness. Crit Care Med (1994) 1.01
Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom. Protein Sci (1992) 1.01
Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol (1993) 1.01
Primary structure of murine major histocompatibility complex alloantigens: isolation, biochemical characterization, and preliminary alignment of CNBr fragments from the H-2Ib glycoprotein. Proc Natl Acad Sci U S A (1978) 1.01
Cancer and venous thromboembolism. Am Heart J (1996) 1.01
Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost (2003) 1.00
Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia (2003) 0.99
Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence studies of the cyanogen bromide fragments of the H-2Kb glycoprotein. Proc Natl Acad Sci U S A (1978) 0.99
Tumor necrosis factor induction of endothelial cell surface antigens is independent of protein kinase C activation or inactivation. Studies with phorbol myristate acetate and staurosporine. J Immunol (1991) 0.99
Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. J Clin Oncol (1998) 0.99
Autologous blood transfusion in revision hip arthroplasty. A prospective, controlled study of 30 patients. Acta Orthop Scand (1992) 0.98
Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation (1995) 0.98
Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol (1997) 0.98
Behavioral characteristics of high- and low-IQ autistic children. Am J Psychiatry (1981) 0.98